According to Catalent's latest financial reports the company's current revenue (TTM) is $4.09 B. In 2022 the company made a revenue of $4.75 B an increase over the years 2021 revenue that were of $4.48 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $4.09 B | -13.85% |
2022 | $4.75 B | 6.11% |
2021 | $4.48 B | 29.38% |
2020 | $3.46 B | 26.96% |
2019 | $2.72 B | 9.7% |
2018 | $2.48 B | 8.19% |
2017 | $2.29 B | 21.29% |
2016 | $1.89 B | 3.35% |
2015 | $1.83 B | -0.66% |
2014 | $1.84 B | 2.19% |
2013 | $1.80 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Supernus Pharmaceuticals
SUPN | $0.60 B | -85.18% | ๐บ๐ธ USA |
Jazz Pharmaceuticals JAZZ | $3.83 B | -6.44% | ๐ฎ๐ช Ireland |
Aerie Pharmaceuticals AERI | $0.21 B | -94.78% | ๐บ๐ธ USA |
Intercept Pharmaceuticals
ICPT | $0.31 B | -92.25% | ๐บ๐ธ USA |